Context:
The client aimed to evaluate time to event outcomes, including overall survival and progression free survival, in breast cancer patients receiving different treatment regimens. The objective was to identify significant risk factors, compare therapeutic effectiveness, and generate statistical evidence to support clinical decision making.

Resolution:
Our team performed structured survival analysis using Kaplan Meier curves to estimate survival probabilities across treatment groups and calculated hazard ratios to quantify treatment effects while assessing statistical significance. Subgroup analyses were conducted based on disease stage and patient characteristics. The findings were documented in comprehensive R Markdown reports to ensure clarity, reproducibility, and regulatory ready presentation.

Result:
Targeted therapy significantly improved survival compared to chemotherapy alone. The analysis provided strong quantitative evidence of treatment effectiveness, supported personalized treatment strategies, and informed future clinical trial design. These insights contributed to improved patient outcomes and more data driven oncology care.